Articles

Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma

Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN
Department of Tumor Biology, H. Lee Moffitt Cancer Research Center and Institute, Tampa, FL
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN
Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR
Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN
Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN, USA; Research Service, Roudebush Veterans Administration Medical Center, Indianapolis, IN
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis IN, USA; Research Service, Roudebush Veterans Administration Medical Center, Indianapolis, IN
Haematologica Early view Nov 16, 2023 https://doi.org/10.3324/haematol.2023.283787